MX2014014648A - Aminoamidas tipo dendrimero que poseen actividad bloqueadora del canal de sodio para el tratamiento de ojo reseco y otras enfermedades mucosas. - Google Patents
Aminoamidas tipo dendrimero que poseen actividad bloqueadora del canal de sodio para el tratamiento de ojo reseco y otras enfermedades mucosas.Info
- Publication number
- MX2014014648A MX2014014648A MX2014014648A MX2014014648A MX2014014648A MX 2014014648 A MX2014014648 A MX 2014014648A MX 2014014648 A MX2014014648 A MX 2014014648A MX 2014014648 A MX2014014648 A MX 2014014648A MX 2014014648 A MX2014014648 A MX 2014014648A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- sodium channel
- dendrimer
- dry eye
- channel blocker
- Prior art date
Links
- 239000003195 sodium channel blocking agent Substances 0.000 title abstract 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 title 1
- 206010013774 Dry eye Diseases 0.000 title 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical class NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 title 1
- 239000000412 dendrimer Substances 0.000 title 1
- 229920000736 dendritic polymer Polymers 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229940125794 sodium channel blocker Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 230000002441 reversible effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
- C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
- C07D241/30—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms in which said hetero-bound carbon atoms are part of a substructure —C(=X)—X—C(=X)—X— in which X is an oxygen or sulphur atom or an imino radical, e.g. imidoylguanidines
- C07D241/32—(Amino-pyrazinoyl) guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
- C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
- C07D241/34—(Amino-pyrazine carbonamido) guanidines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se proporcionan bloqueadores del canal de sodio representados por la fórmula II, en donde las variables estructurales se definen en la presente invención. La presente invención también incluye una variedad de composiciones, combinaciones y métodos de tratamiento utilizando estos bloqueadores de canal de sodio inventivo. Es un objeto de la presente invención proporcionar compuestos que son más potentes y/o se absorben menos rápidamente de las superficies mucosas, tal como superficies oculares, y/o son menos reversibles en comparación con compuestos conocidos. En particular, es un objeto de la presente invención proporcionar métodos de tratamiento que dependan de la rehidratación de las superficies mucosas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261652481P | 2012-05-29 | 2012-05-29 | |
| PCT/US2013/043080 WO2013181232A2 (en) | 2012-05-29 | 2013-05-29 | Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014014648A true MX2014014648A (es) | 2015-09-04 |
Family
ID=49671001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014014648A MX2014014648A (es) | 2012-05-29 | 2013-05-29 | Aminoamidas tipo dendrimero que poseen actividad bloqueadora del canal de sodio para el tratamiento de ojo reseco y otras enfermedades mucosas. |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US8980898B2 (es) |
| EP (2) | EP3366680B1 (es) |
| JP (3) | JP6272312B2 (es) |
| KR (1) | KR102109223B1 (es) |
| CN (1) | CN104334535B (es) |
| AU (2) | AU2013267504B2 (es) |
| BR (1) | BR112014029329A2 (es) |
| CA (1) | CA2872029A1 (es) |
| CY (1) | CY1120397T1 (es) |
| DK (1) | DK2855435T3 (es) |
| EA (2) | EA032734B1 (es) |
| ES (1) | ES2675588T3 (es) |
| HU (1) | HUE039734T2 (es) |
| LT (1) | LT2855435T (es) |
| MX (1) | MX2014014648A (es) |
| MY (1) | MY171122A (es) |
| PH (1) | PH12014502624B1 (es) |
| PL (1) | PL2855435T3 (es) |
| PT (1) | PT2855435T (es) |
| SG (1) | SG11201407867VA (es) |
| SI (1) | SI2855435T1 (es) |
| TR (1) | TR201809148T4 (es) |
| WO (1) | WO2013181232A2 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6858615B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
| JP5529851B2 (ja) | 2008-04-18 | 2014-06-25 | リアタ ファーマシューティカルズ インコーポレイテッド | 抗酸化炎症モジュレーター：ｃ−１７においてアミノ改変およびその他の改変を加えたオレアノール酸誘導体 |
| HUE032851T2 (en) | 2011-06-27 | 2017-11-28 | Parion Sciences Inc | A chemically and metabolically stable dipeptide having strong sodium channel blocking activity |
| AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
| MX2014014648A (es) | 2012-05-29 | 2015-09-04 | Parion Sciences Inc | Aminoamidas tipo dendrimero que poseen actividad bloqueadora del canal de sodio para el tratamiento de ojo reseco y otras enfermedades mucosas. |
| JP6243428B2 (ja) | 2012-09-10 | 2017-12-06 | リアタ ファーマシューティカルズ インコーポレイテッド | オレアノール酸のｃ１７−アルカンジイルおよびアルケンジイル誘導体ならびにその使用方法 |
| SG10201708931XA (en) | 2012-12-17 | 2017-12-28 | Parion Sciences Inc | Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration |
| RU2018138195A (ru) | 2012-12-17 | 2018-12-18 | Пэрион Сайенсиз, Инк. | Соединения 3,5-диамино-6-хлор-n-(n-(4- фенилбутил)карбамимидоил)пиразин-2-карбоксамида |
| SG11201601291QA (en) | 2013-08-23 | 2016-03-30 | Parion Sciences Inc | Dithiol mucolytic agents |
| US9102633B2 (en) | 2013-12-13 | 2015-08-11 | Parion Sciences, Inc. | Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds |
| US20150376145A1 (en) | 2014-06-30 | 2015-12-31 | Parion Sciences, Inc. | Stable sodium channel blockers |
| KR20170108088A (ko) | 2015-01-30 | 2017-09-26 | 패리온 사이언스 인코퍼레이티드 | 신규 모노티올 점액용해제 |
| EP3244893A4 (en) * | 2015-02-18 | 2019-01-09 | Parion Sciences, Inc. | SODIUM CHANNEL BLOCKER FOR SKIN DISEASES |
| JP2018520986A (ja) | 2015-04-30 | 2018-08-02 | パリオン・サイエンシィズ・インコーポレーテッド | ジチオール粘液溶解剤の新規なプロドラッグ |
| GB201610854D0 (en) | 2016-06-21 | 2016-08-03 | Entpr Therapeutics Ltd | Compounds |
| GB201619694D0 (en) | 2016-11-22 | 2017-01-04 | Entpr Therapeutics Ltd | Compounds |
| GB201717051D0 (en) | 2017-10-17 | 2017-11-29 | Enterprise Therapeutics Ltd | Compounds |
| CN109752354A (zh) * | 2017-11-06 | 2019-05-14 | 锐准医光股份有限公司 | 整合米洛光学干涉显微术与荧光显微术的光学切层装置 |
| GB201808093D0 (en) | 2018-05-18 | 2018-07-04 | Enterprise Therapeutics Ltd | Compounds |
| CN109160888B (zh) * | 2018-10-09 | 2022-03-01 | 四川医立特生物医药有限公司 | 一种含脒基的对称化合物及其应用 |
| CA3209427A1 (en) * | 2021-01-25 | 2022-07-28 | Phamri Norden Ab | Method of treating a skin disorder |
| CN117164483A (zh) * | 2023-09-07 | 2023-12-05 | 吉尔生化（上海）有限公司 | 一种Cbz-精氨酸叔丁酯的合成方法 |
Family Cites Families (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE639386A (es) | 1962-10-30 | |||
| US3361306A (en) | 1966-03-31 | 1968-01-02 | Merck & Co Inc | Aerosol unit dispensing uniform amounts of a medically active ingredient |
| US3565070A (en) | 1969-02-28 | 1971-02-23 | Riker Laboratories Inc | Inhalation actuable aerosol dispenser |
| US4312860A (en) | 1980-10-24 | 1982-01-26 | Regents Of The University Of California | Lung surfactant compositions |
| US4540564A (en) | 1982-05-18 | 1985-09-10 | University Of Florida | Brain-specific drug delivery |
| US4479932A (en) | 1982-05-18 | 1984-10-30 | University Of Florida | Brain-specific drug delivery |
| US4805811A (en) | 1985-03-29 | 1989-02-21 | Aktiebolaget Draco | Dosage device |
| US5385938B1 (en) * | 1986-12-23 | 1997-07-15 | Tristrata Inc | Method of using glycolic acid for treating wrinkles |
| US5100806A (en) | 1989-03-24 | 1992-03-31 | Macri James N | Method for detecting Edwards syndrome |
| US4955371A (en) | 1989-05-08 | 1990-09-11 | Transtech Scientific, Inc. | Disposable inhalation activated, aerosol device for pulmonary medicine |
| CA2063273C (en) | 1989-07-11 | 2002-09-24 | Bradley J. Benson | Surfactant compositions and methods |
| DE4003272A1 (de) | 1990-02-03 | 1991-08-08 | Boehringer Ingelheim Kg | Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen |
| US5614216A (en) | 1990-10-17 | 1997-03-25 | The Liposome Company, Inc. | Synthetic lung surfactant |
| US5292498A (en) | 1991-06-19 | 1994-03-08 | The University Of North Carolina At Chapel Hill | Method of treating lung disease with uridine triphosphates |
| DE69230613T2 (de) | 1991-07-02 | 2000-12-28 | Inhale Inc | Verfahren und vorrichtung zum abgeben von medikamenten in aerosolform |
| US7105152B1 (en) | 1991-12-18 | 2006-09-12 | 3M Innovative Properties Company | Suspension aerosol formulations |
| JP3908269B2 (ja) | 1991-12-18 | 2007-04-25 | スリーエム カンパニー | 懸濁エアゾール製剤 |
| US5261538A (en) | 1992-04-21 | 1993-11-16 | Glaxo Inc. | Aerosol testing method |
| AUPM411494A0 (en) | 1994-02-25 | 1994-03-24 | Central Sydney Area Health Service | Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum |
| US5522385A (en) | 1994-09-27 | 1996-06-04 | Aradigm Corporation | Dynamic particle size control for aerosolized drug delivery |
| US5622163A (en) | 1994-11-29 | 1997-04-22 | Iep Group, Inc. | Counter for fluid dispensers |
| US5544647A (en) | 1994-11-29 | 1996-08-13 | Iep Group, Inc. | Metered dose inhalator |
| US5656256A (en) | 1994-12-14 | 1997-08-12 | The University Of North Carolina At Chapel Hill | Methods of treating lung disease by an aerosol containing benzamil or phenamil |
| HU219899B (hu) | 1995-04-14 | 2001-09-28 | Glaxo Wellcome Inc. | Inhalálóberendezés flutikaszon-propionát adagolására mért dózisban |
| CN1262556C (zh) | 1997-02-06 | 2006-07-05 | 印斯拜尔药品股份有限公司 | 特定的二核苷酸和它们作为粘膜纤毛清除和纤毛颤动频率调节剂的应用 |
| US7223744B2 (en) | 1997-02-10 | 2007-05-29 | Inspire Pharmaceuticals, Inc. | Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof |
| US6818629B2 (en) | 1997-02-10 | 2004-11-16 | Inspire Pharmaceuticals, Inc. | Pharmaceutical formulation comprising P1-(2'-deoxycytidine 5'-)P4-(uridine 5'-) tetraphosphate |
| US20010031244A1 (en) | 1997-06-13 | 2001-10-18 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
| GB9807232D0 (en) | 1998-04-03 | 1998-06-03 | Univ Cardiff | Aerosol composition |
| US7105552B2 (en) | 1998-05-08 | 2006-09-12 | Theracos, Inc. | Heterocyclic analogs of diphenylethylene compounds |
| EP1143896B1 (en) | 1998-10-20 | 2006-12-13 | The University of North Carolina at Chapel Hill | Methods of hydrating the nasal mucosal surface |
| US6926911B1 (en) | 1998-12-22 | 2005-08-09 | The University Of North Carolina At Chapel Hill | Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs |
| US6329034B1 (en) | 1999-01-18 | 2001-12-11 | Roger L. Pendry | Label having tab member and methods for forming, applying and using the same |
| US6116234A (en) | 1999-02-01 | 2000-09-12 | Iep Pharmaceutical Devices Inc. | Metered dose inhaler agitator |
| EP1183061B2 (en) | 1999-06-05 | 2012-10-17 | Innovata Biomed Limited | Medicament delivery system |
| GB2353222B (en) | 1999-06-23 | 2001-09-19 | Cambridge Consultants | Inhalers |
| GB9920839D0 (en) | 1999-09-04 | 1999-11-10 | Innovata Biomed Ltd | Inhaler |
| US6880555B1 (en) | 1999-10-12 | 2005-04-19 | Shl Medical Ab | Inhaler |
| NZ518401A (en) | 1999-10-29 | 2004-01-30 | Nektar Therapeutics | Dry powder compositions having improved dispersivity |
| GB9928265D0 (en) | 1999-12-01 | 2000-01-26 | Innovata Biomed Ltd | Inhaler |
| SE9904706D0 (sv) | 1999-12-21 | 1999-12-21 | Astra Ab | An inhalation device |
| US7345051B2 (en) | 2000-01-31 | 2008-03-18 | Genaera Corporation | Mucin synthesis inhibitors |
| US7171965B2 (en) | 2000-02-01 | 2007-02-06 | Valois S.A.S. | Breath actuated dry powder inhaler and tape dose strip |
| FR2813593B1 (fr) | 2000-09-07 | 2002-12-06 | Valois Sa | Dispositif de distribution de produit fluide de type multidose |
| GB0026647D0 (en) | 2000-10-31 | 2000-12-13 | Glaxo Group Ltd | Medicament dispenser |
| US6858615B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
| US6858614B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenolic guanidine sodium channel blockers |
| US6889690B2 (en) | 2002-05-10 | 2005-05-10 | Oriel Therapeutics, Inc. | Dry powder inhalers, related blister devices, and associated methods of dispensing dry powder substances and fabricating blister packages |
| AU2003256755A1 (en) | 2002-07-24 | 2004-02-09 | Ptc Therapeutics, Inc. | Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations |
| US6903105B2 (en) | 2003-02-19 | 2005-06-07 | Parion Sciences, Inc. | Sodium channel blockers |
| HUE047569T2 (hu) | 2003-04-11 | 2020-04-28 | Ptc Therapeutics Inc | 1,2,4-oxadiazol-benzoesav vegyület és nonszensz szupresszióra történõ alkalmazása |
| EP1488819A1 (en) | 2003-06-16 | 2004-12-22 | Rijksuniversiteit te Groningen | Dry powder inhaler and method for pulmonary inhalation of dry powder |
| US20050090505A1 (en) | 2003-08-18 | 2005-04-28 | Johnson Michael R. | Methods of reducing risk of infection from pathogens |
| AU2004266704B2 (en) | 2003-08-18 | 2012-02-23 | Parion Sciences, Inc. | Capped pyrazinoylguanidine sodium channel blockers |
| US7375107B2 (en) | 2003-08-18 | 2008-05-20 | Parion Sciences, Inc. | Alaphatic pyrazinoylguanidine sodium channel blockers |
| JP2007502829A (ja) | 2003-08-18 | 2007-02-15 | パリオン・サイエンシィズ・インコーポレーテッド | 環状ピラジノイルグアニジンナトリウムチャネルブロッカー |
| US20090253714A1 (en) | 2003-08-20 | 2009-10-08 | Johnson Michael R | Methods of reducing risk of infection from pathogens |
| US7745442B2 (en) | 2003-08-20 | 2010-06-29 | Parion Sciences, Inc. | Methods of reducing risk of infection from pathogens |
| US7499570B2 (en) | 2004-03-02 | 2009-03-03 | Siemens Corporate Research, Inc. | Illumination invariant change detection |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| US7375102B2 (en) | 2004-06-28 | 2008-05-20 | Amgen Sf, Llc | Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use |
| US20090324724A1 (en) | 2004-08-18 | 2009-12-31 | Parion Sciences, Inc. | Soluble amide & ester pyrazinoylguanidine sodium channel blockers |
| WO2006023617A2 (en) | 2004-08-18 | 2006-03-02 | Johnson Michael R | Cyclic amide & ester pyrazinoylguanidine sodium channel blockers |
| CA2575670A1 (en) * | 2004-08-18 | 2006-03-02 | Michael R. Johnson | Aliphatic amide & ester pyrazinoylguanidine sodium channel blockers |
| US7399766B2 (en) | 2004-08-18 | 2008-07-15 | Parion Sciences, Inc. | Soluble amide & ester pyrazinoylguanidine sodium channel blockers |
| EP2402323A3 (en) | 2004-10-13 | 2012-05-30 | PTC Therapeutics, Inc. | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases |
| JP2009221164A (ja) | 2008-03-17 | 2009-10-01 | Nitto Denko Corp | 肺線維症処置剤 |
| CN102600480B (zh) | 2005-01-07 | 2015-07-22 | 阿尔尼拉姆医药品有限公司 | RSV的RNAi调节及其治疗应用 |
| US7588817B2 (en) | 2005-03-11 | 2009-09-15 | Jds Uniphase Corporation | Engraved optically variable image device |
| US20070021439A1 (en) * | 2005-07-25 | 2007-01-25 | Parion Sciences, Inc. | Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers |
| US7807834B2 (en) | 2005-08-03 | 2010-10-05 | Parion Sciences, Inc. | Capped pyrazinoylguanidine sodium channel blockers |
| EP2036567A3 (en) | 2005-12-06 | 2009-12-09 | P2-Science APS | Modulation of the P2Y2 receptor pathway |
| AU2006331565A1 (en) | 2005-12-27 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Compounds useful in CFTR assays and methods therewith |
| CN101404980A (zh) | 2006-01-24 | 2009-04-08 | 耐百生物制药有限公司 | 大分子微球的制备技术 |
| US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| EP2021797B1 (en) | 2006-05-12 | 2011-11-23 | Vertex Pharmaceuticals, Inc. | Compositions of n-ý2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl¨-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| TWI334164B (en) | 2006-06-07 | 2010-12-01 | Ind Tech Res Inst | Method of manufacturing nitride semiconductor substrate and composite material substrate |
| US8324218B2 (en) * | 2006-06-09 | 2012-12-04 | Parion Sciences, Inc. | Aliphatic pyrazinoylguanidine sodium channel blockers with beta agonist activity |
| PT2035004E (pt) | 2006-06-09 | 2012-11-21 | Parion Sciences Inc | Bloqueadores dos canais de sódio de pirazinoilguanidona substituída com fenilo que possuem actividade agonista beta |
| US20110195973A1 (en) | 2006-06-09 | 2011-08-11 | Parion Sciences, Inc. | Cyclic substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity |
| TW200819430A (en) | 2006-09-07 | 2008-05-01 | Michael R Johnson | Enhanced mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes |
| AU2007294547A1 (en) | 2006-09-07 | 2008-03-13 | Parion Sciences, Inc. | Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes |
| CN101534813A (zh) * | 2006-09-07 | 2009-09-16 | 帕里昂科学公司 | 通过使用钠通道阻断剂和渗透调节剂的治疗来增加粘膜水化和粘液清除的方法 |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
| US8288391B2 (en) * | 2007-04-03 | 2012-10-16 | Parion Sciences, Inc. | Pyrazinoylguanidine compounds for use as taste modulators |
| US20080293740A1 (en) | 2007-04-03 | 2008-11-27 | Parion Sciences, Inc. | Method of treating acid-sensing ion channel mediated pain, cough suppression, and central nervous system disorders |
| JP2010527914A (ja) | 2007-04-26 | 2010-08-19 | クォーク ファーマシューティカルズ インコーポレーティッド | 呼吸器系への抑制性核酸分子の治療的送達 |
| EP1997502A1 (en) | 2007-06-01 | 2008-12-03 | CHIESI FARMACEUTICI S.p.A. | Reconstituted surfactants having improved properties |
| DK2011907T3 (da) | 2007-07-02 | 2010-05-17 | Centre Nat Rech Scient | Fremgangsmåde til fremstilling af hydrogengas og carbon-nanorør ud fra en katalytisk nedbrydning af ethanol |
| US8131579B2 (en) | 2007-07-09 | 2012-03-06 | Raytheon Company | Web-based system and application for collaborative planning of a networked program schedule |
| AU2008279129A1 (en) | 2007-07-24 | 2009-01-29 | Nexbio, Inc. | Technology for the preparation of microparticles |
| US8551534B2 (en) | 2007-10-10 | 2013-10-08 | Parion Sciences, Inc. | Inhaled hypertonic saline delivered by a heated nasal cannula |
| EP2217249A4 (en) | 2007-11-06 | 2011-10-12 | Benaroya Res Inst | INHIBITION OF VERSICAN WITH SIRNA AND OTHER MOLECULES |
| WO2009139948A1 (en) | 2008-02-26 | 2009-11-19 | Johnson Michael R | Poly aromatic sodium channel blockers |
| NZ720282A (en) | 2008-02-28 | 2017-12-22 | Vertex Pharma | Heteroaryl derivatives as cftr modulators |
| EP2271621B1 (en) | 2008-03-31 | 2013-11-20 | Vertex Pharmaceuticals Incorporated | Pyridyl derivatives as cftr modulators |
| US20100074881A1 (en) | 2008-07-11 | 2010-03-25 | Parion Sciences, Inc. | Multiple nebulizer systems |
| PT2358680E (pt) | 2008-10-23 | 2013-05-14 | Vertex Pharma | Formas sólidas de n-(4-(7-azabiciclo[2.2.1]heptan-7-il)-2- (trifluorometil)fenil)-4-oxo- 5-(trifluorometil)-1,4- dihidroquinolina-3-carboxamida |
| US20100316628A1 (en) | 2008-12-09 | 2010-12-16 | The General Hospital Corporation | Agents and methods for treating respiratory disorders |
| EP2382197B1 (en) | 2008-12-30 | 2016-10-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
| HUE032851T2 (en) | 2011-06-27 | 2017-11-28 | Parion Sciences Inc | A chemically and metabolically stable dipeptide having strong sodium channel blocking activity |
| MX2014014648A (es) | 2012-05-29 | 2015-09-04 | Parion Sciences Inc | Aminoamidas tipo dendrimero que poseen actividad bloqueadora del canal de sodio para el tratamiento de ojo reseco y otras enfermedades mucosas. |
| SG10201708931XA (en) | 2012-12-17 | 2017-12-28 | Parion Sciences Inc | Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration |
| RU2018138195A (ru) | 2012-12-17 | 2018-12-18 | Пэрион Сайенсиз, Инк. | Соединения 3,5-диамино-6-хлор-n-(n-(4- фенилбутил)карбамимидоил)пиразин-2-карбоксамида |
-
2013
- 2013-05-29 MX MX2014014648A patent/MX2014014648A/es active IP Right Grant
- 2013-05-29 JP JP2015515146A patent/JP6272312B2/ja not_active Expired - Fee Related
- 2013-05-29 CN CN201380028574.3A patent/CN104334535B/zh not_active Expired - Fee Related
- 2013-05-29 EA EA201491816A patent/EA032734B1/ru not_active IP Right Cessation
- 2013-05-29 PT PT137975991T patent/PT2855435T/pt unknown
- 2013-05-29 HU HUE13797599A patent/HUE039734T2/hu unknown
- 2013-05-29 PL PL13797599T patent/PL2855435T3/pl unknown
- 2013-05-29 TR TR2018/09148T patent/TR201809148T4/tr unknown
- 2013-05-29 ES ES13797599.1T patent/ES2675588T3/es active Active
- 2013-05-29 DK DK13797599.1T patent/DK2855435T3/en active
- 2013-05-29 EA EA201990616A patent/EA201990616A3/ru unknown
- 2013-05-29 SG SG11201407867VA patent/SG11201407867VA/en unknown
- 2013-05-29 CA CA2872029A patent/CA2872029A1/en not_active Abandoned
- 2013-05-29 LT LTEP13797599.1T patent/LT2855435T/lt unknown
- 2013-05-29 EP EP18166275.0A patent/EP3366680B1/en active Active
- 2013-05-29 KR KR1020147033219A patent/KR102109223B1/ko not_active Expired - Fee Related
- 2013-05-29 SI SI201331073T patent/SI2855435T1/sl unknown
- 2013-05-29 BR BR112014029329A patent/BR112014029329A2/pt not_active Application Discontinuation
- 2013-05-29 AU AU2013267504A patent/AU2013267504B2/en not_active Ceased
- 2013-05-29 US US13/904,634 patent/US8980898B2/en not_active Expired - Fee Related
- 2013-05-29 WO PCT/US2013/043080 patent/WO2013181232A2/en not_active Ceased
- 2013-05-29 MY MYPI2014003078A patent/MY171122A/en unknown
- 2013-05-29 EP EP13797599.1A patent/EP2855435B1/en not_active Not-in-force
-
2014
- 2014-11-24 PH PH12014502624A patent/PH12014502624B1/en unknown
- 2014-12-09 US US14/564,299 patent/US9260398B2/en not_active Expired - Fee Related
-
2016
- 2016-01-05 US US14/988,540 patent/US9878988B2/en not_active Expired - Fee Related
-
2017
- 2017-12-20 US US15/849,454 patent/US10526292B2/en not_active Expired - Fee Related
- 2017-12-27 JP JP2017251389A patent/JP2018058897A/ja active Pending
-
2018
- 2018-01-16 AU AU2018200363A patent/AU2018200363B2/en not_active Ceased
- 2018-07-06 CY CY20181100713T patent/CY1120397T1/el unknown
-
2019
- 2019-12-05 JP JP2019220478A patent/JP2020059732A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014502624A1 (en) | Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases | |
| MX368263B (es) | Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica. | |
| IN2015DN02573A (es) | ||
| HK1243322A1 (zh) | 脂肪酸半胱胺缀合物和它们作为自噬的活化剂的用途 | |
| EA201892147A1 (ru) | Бициклические соединения | |
| EA201692526A1 (ru) | Замещенные [1,2,4]триазольные соединения | |
| AU2015207757A8 (en) | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2 | |
| CA2902795C (en) | Glycopyrrolate salts | |
| PH12018501575A1 (en) | Indolinones compounds and their use in the treatment of fibrotic diseases | |
| EA033460B1 (ru) | Замещенные [1,2,4]триазольные соединения в качестве фунгицидов | |
| PH12015500310A1 (en) | Pyrrolopyrazoles as n-type calcium channel blockers | |
| MX2014009750A (es) | Composiciones antifungicas para el tratamiento de piel y uñas. | |
| WO2012017321A3 (en) | Treatment for dyslipidemia | |
| MD4780B1 (ro) | Urei asimetrice p-substituite şi utilizările medicale ale acestora | |
| EA201591434A1 (ru) | Способ обеспечения глазной нейропротекции | |
| WO2015077535A3 (en) | Novel methods for treating neurodegenerative diseases | |
| EA201491581A1 (ru) | Везикулярные композиции | |
| IN2013DE02503A (es) | ||
| WO2012082942A3 (en) | Neuropeptide analogs, compositions, and methods for treating pain | |
| EA201591449A1 (ru) | Способы получения противораковых композиций | |
| PH12015500314A1 (en) | Cyclopentylpyrazoles as n-type calcium channel blockers | |
| PH12015502703A1 (en) | Pharmaceutical compositions | |
| MX2015007460A (es) | Agentes para el tratamiento del dolor y usos de los mismos. | |
| WO2014049563A3 (en) | Use of a combination of taurine or a derivate thereof and a grape extract for improving the quality of the nails | |
| WO2014102820A3 (en) | Rivaroxaban intermediate and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |